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Value and Limitations of Existing Scores
for the Assessment of Cardiovascular Risk
A Review for Clinicians
Marie Therese Cooney, MB, BCH, BAO, Alexandra L. Dudina, MB,
Ian M. Graham, MB, BCH, BAO, BA
Dublin, Ireland
Atherosclerotic cardiovascular diseases (CVDs) are the biggest causes of death worldwide. In most people, CVD
is the product of a number of causal risk factors. Several seemingly modest risk factors may, in combination,
result in a much higher risk than an impressively raised single factor. For this reason, risk estimation systems
have been developed to assist clinicians to assess the effects of risk factor combinations in planning manage-
ment strategies. In this article, the performances of the major risk estimation systems are reviewed. Most per-
form usably well in populations that are similar to the one used to derive the system, and in other populations if
calibrated to allow for different CVD mortality rates and different risk factor distributions. The effect of adding
“new” risk factors to age, sex, smoking, lipid status, and blood pressure is usually small, but may help to appro-
priately reclassify some of those patients who are close to a treatment threshold to a more correct “treat/do not
treat” category. Risk estimation in the young and old needs more research. Quantification of the hoped-for bene-
fits of the multiple risk estimation approach in terms of improved outcomes is still needed. But, it is likely that
the widespread use of such an approach will help to address the issues of both undertreatment and
overtreatment. (J Am Coll Cardiol 2009;54:1209–27) © 2009 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.020c
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atherosclerotic cardiovascular diseases (CVDs) are the big-
est causes of death worldwide (1). Decades of research have
etermined that atherosclerosis develops insidiously, is often
dvanced by the time that symptoms occur, but may then
ill rapidly. It follows that treatments may be inapplicable if
he person dies rapidly, or palliative even if they survive long
nough to reach medical care (2). While this is not to
ainsay the wonderful advances in therapy that have oc-
urred, it is clearly desirable to determine the causes of CVD
nd to see if such knowledge can translate into effective
reventive strategies.
In this review, we define the term “risk factor” and outline
he concept of and rationale for total risk estimation. The
haracteristics of a clinically useful risk estimation system
re tabulated. Current risk estimation systems are described
nd compared. Substantial limitations are common to all
isk estimation systems, and we describe these and outline
hat is being done to deal with them, including recalibra-
ion, the effect of incorporating newer risk factors, and the
hallenges of risk estimation in the young and the old. We
rom the Adelaide Meath Hospital, Tallaght, Dublin, Ireland.n
Manuscript received May 7, 2009; revised manuscript received July 13, 2009,
ccepted July 20, 2009.onclude by looking at the evidence—or lack of it—that a
otal risk estimation approach is likely to improve outcome.
otal CVD Risk Assessment
century of intensive research has taught us that the mass
ccurrence of CVD relates to interlocking genetic, social,
hysiological, and environmental factors. A comprehensive
pproach to prevention would address all of these. While
waiting major advances in genetics and the ability to reduce
ocial inequalities, it has become evident that certain factors
ctually cause atherosclerosis, and that their modification
an reduce mortality—especially with regard to smoking
essation and the effective control of blood pressure and
lood cholesterol.
A risk factor may be defined as a characteristic of a person
hat is associated with an increased risk of developing a
pecific disease such as atherosclerotic CVD. To be clini-
ally relevant, it should be accepted as causal (3) and
odifiable, and a defined benefit should result from such
odification. Most risk estimation systems include age, sex,
moking, blood lipids, and blood pressure as their core
ariables. In this context, age is a measure of exposure time
nd not a risk factor as such.
The term “total risk estimation” is perhaps a misnomer, as
o risk estimation system accommodates all known risk
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Cardiovascular Risk Estimation Systems September 29, 2009:1209–27factors. However, it refers to the
fact that CVD, in most people,
is the product of several risk
factors that may interact to
greatly increase risk, and an ap-
proach that focuses on single
risk factors may result in inap-
propriate management deci-
sions. Looking at Table 1, taken
from the current Joint European
Guidelines on the prevention of
CVD in clinical practice (2), who
should receive the statin? The
60-year-old woman with a blood
holesterol level of 8 mmol/l (309 mg/dl) and a 2% 10-year
isk of fatal CVD, or the man of the same age with a
holesterol of 5 mmol/l (193 mg/dl) but a 10-fold higher
isk because of multiple other risk factors? Current thera-
eutic trial data do not tell us, but logic would suggest the
an, along with, of course, attention to all other factors.
These considerations have led the authors of all current
uidelines to stress the need to consider the likely impact of
ll risk factors before making clinical management decisions
nd, in most cases, to recommend a system of evaluating
ombined risk factor effects (2,4–6).
In regard to risk estimation and management, McGor-
ian et al. (7) define 4 challenges that face the busy health
rofessional: 1) How do I identify people who are at
ncreased risk of a cardiovascular event? 2) How do I weight
he individual effects of all the causative risk factors when
ssessing a person’s risk? 3) How do I stratify that risk to
etermine who needs lifestyle advice and who needs addi-
ional medical therapy? 4) How do I ensure that I am not
vermedicalizing those persons who are at low risk of an
vent?
Risk estimation systems provide some tools that may
ssist the health care professional. The criteria for a clini-
ally useful risk estimation system are outlined in Table 2.
urrent Risk Estimation Systems
any risk estimations systems are in existence (8–14). The
est known and probably the most widely used, globally, is
he Framingham risk score (8). The Framingham group also
ioneered many of the methods commonly used in risk
stimation (15,16). Several modified versions of the Fra-
ingham function have also been developed and presented
Abbreviations
and Acronyms
AUROC  area under the
receiver-operating
characteristic curve
CHD  coronary heart
disease
CRP  C-reactive protein
CVD  cardiovascular
disease
NRI  net reclassification
index
mpact of Combinations of Risk Factors on Total CVD RiskTable 1 I pact of Combinations of Risk Factors on Total CVD
Sex Age (Yrs) Total Cholesterol, mmol/l (mg/dl) SB
Female 60 8 (309)
Female 60 7 (271)
Male 60 6 (232)
Male 60 5 (193)VD  cardiovascular disease; SBP  systolic blood pressure; SCORE  Systematic COronary Risk Evalus either charts or tables and have been included in national
nd international guidelines (17,18). Table 3 details the
haracteristics of the Framingham function and allows
omparison with some other commonly used systems. Re-
ently, several other systems have been introduced offering
dvantages in terms of inclusion of extra risk factors, and so
orth. However, in this review, we have concentrated mainly
n those systems that are recommended by guidelines on
VD prevention (8–14). Most current risk estimation
ystems calculate the absolute risk of CVD events; that is
ogical but can be problematic for younger people. This
ssue is addressed fully in the “Risk Estimation in Younger
ersons” section in the following text.
The risk estimation systems will be compared based on
he characteristics that we consider to be important for risk
stimation systems, as detailed in Table 2.
ethods
he Framingham and the ASSIGN scoring systems are
ased on intermediate-sized samples that are representative
f the general population (8,10). The PROCAM (Prospec-
ive Cardiovascular Münster) study is based on a sample of
ndustrial employees (12); it may be considered somewhat
nderpowered for risk estimation for women (49 events).
he SCORE (Systematic COronary Risk Evaluation) sys-
em is based on a substantially larger dataset that contains
205,000 persons, representing 2.1 million person-years of
bservation (9). Because it is a pooled dataset of 12
uropean prospective studies, it has the potential to accom-
odate more of the heterogeneity across Europe in terms of
aseline CVD risk. The majority of the included studies are
epresentative of the general population, although in the
ower-risk European countries, some occupational cohorts
ere also included (9).
The QRISK (19) and QRISK2 (11) systems are different
ecause they are based on databases of general practice
ttendees and are, therefore, not random representative
amples of the population; additionally, the baseline risk
actor measurements would have been obtained at varying
imes during the observation period, methods were not
tandardized, and there are substantial amounts of missing
ata, which were imputed as part of the analysis. However,
he advantage of using these data is the substantially larger
umbers that can be included; QRISK2 included 1.5
illion people (11). Additionally, these systems, based on
eneral practice registers, have the potential for ongoing
Hg) Current Smoker SCORE Risk (% 10-Yr Risk of Fatal CVD)
No 2
Yes 5
No 8
Yes 21Risk
P (mm
120
140
160
180ation.
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September 29, 2009:1209–27 Cardiovascular Risk Estimation Systemsevisions utilizing newer data (36,37). The Reynolds risk
cores use a different approach again; these scores, which
ave been derived separately for men and women, are based
n the prospective follow-up of 2 separate randomized
ontrolled trials (20,21).
The choice of end point predicted by the function is also
consideration. Early systems usually estimated coronary
eart disease (CHD) risk (16). Because atherosclerosis may
anifest elsewhere, for example, as stroke or peripheral
ascular disease, more recent systems have tended to use
otal CVD as the primary end point (8,9). It is, however,
elpful to retain the capacity to estimate risk of cause-
pecific events, because stroke, for example, may be propor-
ionately more common in certain populations such as
ow-risk countries and older persons (38).
The end point should be as clearly defined as possible to
revent coding difficulties when the function is applied to
xternal populations. This was a problem with initial ver-
ions of the Framingham function, which included “softer”
nd points, including onset of angina of effort and silent
yocardial infarctions based on electrocardiographic re-
xaminations (15). Additionally, this end point did not
orrespond to the end points used in clinical trials. More
ecent versions have been based solely on “harder” end
oints (8) or have allowed an option for calculation of risk
f harder end points (16). The SCORE system estimates
riteria for a Clinically Useful Risk Estimation SystemTable 2 Criteria for a Clinically Useful Risk Estimation System
Appropriate statistical methods for derivation of the function
Representative sample from the population from which the system is to be applie
Sufficient power (large enough sample size)
Accepted statistical methods
The end point predicted by the function should be defined in such a way that it is
controlled trials of preventive measures
Performance of the function—internal and external validity
Discrimination: the ability of the function to separate those who will develop the e
Area under receiver operating characteristic curve (AUROC)—a means for express
discrimination; 0.5 equates to chance. Values in the region of 0.9 are often a
statistic gives the same information but can be used with variable follow-up.
Sensitivity/specificity/positive predictive value/negative predictive value
Calibration—a measure of how closely predicted outcomes agree with actual outc
Hosmer-Lemeshow goodness of fit testing—lower values indicate better fit, values
Predicted to observed ratios—the closer the value to 1, the better the fit. Values 
Reclassification
Net reclassification index—a measure of the net percentage of those who do a
a different risk category when a new risk factor is added to the risk estimati
Usability of the system
The format affects the ease of use of the system. This will also impact on the upt
Inclusion of appropriate risk factors
Most risk estimation systems include age, sex and conventional risk factors includ
Inclusion of other factors may be important, especially if they have been shown to
to be applied (e.g., social deprivation).
Some advocate the use of only risk factors that are potentially modifiable, althoug
improve risk estimation because those identified as high risk can still modify
Systems using only easily measured non–laboratory measures have been develop
Has use of the system been shown to result in measurable health gains?isk of fatal CVD events only, whereas the other systems in table 3 estimate risk of CHD/CVD events (9). Some
onsider this a disadvantage; however, this very clear end
oint definition was specifically chosen because it was
ubject to less variation in terms of coding and end point
scertainment when being applied across 12 different cohort
tudies (9). The ease of application of this definition also
ids the recalibration process, as will be discussed in the
ollowing text.
tatistical Considerations
ost of the current risk estimation systems are based on
roportional hazards models—either Cox (semiparametric)
8,10,11,20,21) or Weibull (parametric) (9,12). Logistic
egression had been used previously, but these newer meth-
ds afforded the advantage of allowing for losses to
ollow-up and variable observation time within the cohort.
he Cox method has the advantage of not making any
ssumptions regarding the shape of the underlying survival,
n contrast to the Weibull method, which imposes a
arametric function on the baseline survival. Weibull was
hosen for the original SCORE function and age was
ncluded as part of the time variable, as opposed to as a risk
actor, which allowed the effect of age to vary at different
ges (9). This method also makes more efficient use of the
ata by allowing risk to be estimated for periods greater than
standardized across populations and relevant to the outcomes of randomized
int from those who will not. Often assessed using:
maximum achievable sensitivity and specificity. An AUROC of 1 indicates perfect
d for diagnostic tests. Values rarely exceed 0.8 for risk estimation. Harrell’s C
Often assessed using either:
generally considered good fit. Significant p values indicate lack of fit.
icate overestimation and vice versa.
not develop the end point within the time period that are correctly reclassified to
em.
the system by users.
id levels, smoking, and blood pressure.
werful risk determinations and prevalent in the population to which to system is
t agree that risk factors to be included should be chosen based on whether they
risk by favorably altering their other risk factors.
ently.d
easily
nd po
ing the
chieve
omes.
20
1 ind
nd who
on syst
ake of
ing lip
be po
h mos
their
ed reche length of the study’s follow-up (9). This advantage of
Characteristics of Current Risk Estimation Systems (WHO/ISH)Table 3 Characteristics of Current Risk Estimation Systems (WHO/ISH)
Framingham (8) SCORE (9) ASSIGN – SCORE (10) QRISK1 (19) and QRISK2 (11) PROCAM (12) WHO/ISH (14) Reynolds Risk Score (20,21)
Data Prospective studies:
Framingham Heart
Study and Framingham
Offspring Study
Latest version includes
both
12 pooled prospective
studies from 11
European countries
SHHEC prospective study QRESEARCH database Prospective study Methods differ to other risk
estimation functions—not
based on prospective data
Randomized controlled trials
Women: Women’s Health
Study
Men: Physician’s Health Study II
Population and
sample type
General population,
Framingham, Mass,
U.S. Volunteer
Mostly random samples
from general
population, some
occupational cohorts
Random sample from
general population in
Scotland
Health records of general practice
attendees—not random
Healthy employees
Volunteer—not random
Not applicable Women: Health Service
employees
Men: Physicians
Volunteer—not random
Baseline of data Baselines: 1968–1971,
1971–1975,
1984–1987
Baselines: 1972–1991 Baseline: 1984–1987 Baseline: 1993–2008 Baseline: 1978–1995 Women baseline: 1993–1996
Men baseline: 1997
Sample size 3,969 men and
4.522 women
117,098 men and
88,080 women
6,540 men and
6,757 women
1.28 million (QRISK1)
2.29 million (QRISK2)
18,460 men and
8,515 women
Not applicable 24,558 women and
10,724 men
Statistical
methods
Cox (Weibull—earlier
versions) (15)
Cox and Weibull Cox Imputation of substantial
missing data
Cox
Cox and Weibull
Exploratory analyses with
neural networks also (22)
Relative risks associated with
risk factors were taken
from comparative risk
assessment project; these
were combined with
estimated absolute risks
for each WHO subregion
based on global burden of
disease study
Cox
Calculates 10-yr risk of CHD events
originally
Latest version: 10-year
risk of CVD events
Risk age
10-yr risk of CVD mortality 10-yr risk of CVD events 10-yr risk of CVD events 2 separate scores calculate
10-yr risks of major
coronary events and
cerebral ischemic events
10-yr risk of CVD events 10-yr risk of incident
myocardial infarction,
stroke, coronary
revascularization, or
cardiovascular death
Age range 30–75 yrs 40–65 yrs 30–74 yrs 35–74 yrs 20–75 yrs 40–79 yrs 45–80 yrs
Variables Sex, age, total cholesterol,
HDL cholesterol, SBP,
smoking status,
diabetes, hypertensive
treatment
Sex, age, total cholesterol
or total cholesterol/
HDL cholesterol ratio,
SBP, smoking status
Versions for use in high-
and low-risk countries
Sex, age, total cholesterol,
HDL cholesterol, SBP,
Smoking—no. of
cigarettes, diabetes,
area-based index of
deprivation, family
history of CHD
QRISK1—sex, age, total
cholesterol to HDL cholesterol
ratio, SBP, smoking status,
diabetes, area-based index of
deprivation, family history, BMI,
antihypertensive treatment
QRISK2—also includes ethnicity
and chronic diseases
Age, sex, LDL cholesterol,
HDL cholesterol, diabetes,
smoking, SBP
Sex, age, SBP, smoking
status, diabetes  total
cholesterol; different charts
available for worldwide
regions
Sex, age, SBP, smoking,
hsCRP, total cholesterol,
HDL cholesterol, family
history of premature MI
(parent age 60 yrs),
HbA1C if diabetic
Formats Simplified scoring sheets;
color charts have been
generated for some
guidelines (e.g., JBS and
New Zealand guidelines);
online calculators;
portable calculators
Color-coded charts, Heart
Score—online and CD-
based stand-alone
electronic versions
Online calculator Online calculator Simple scoring sheet and
online calculators
Color-coded charts Online calculator
Continued on next page
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ContinuedTable 3 Continued
Framingham (8) SCORE (9) ASSIGN – SCORE (10) QRISK1 (19) & QRISK2 (11) PROCAM (12) WHO/ISH (14) Reynolds Risk Score (20,21)
Developments Latest version includes
version based on non-
laboratory values only,
substituting BMI from
lipid measurements
National, updated
recalibrations
— QRISK2 includes interaction
terms to adjust for the
interactions between age and
some of the variables
Recent change in the
methods (Weibull) allows
allows extension of risk
estimation to women and
broader age range
— —
Recommended
by guidelines
NCEP guidelines (23),
other national
guidelines recommend
adapted versions,
including New
Zealand (18)
European guidelines on
CVD prevention (2)
Recommended by SIGN
(Scottish Intercollegiate
Guidelines Network) (24)
NICE guidelines on lipid
modification (25)
International Task Force for
Prevention of Coronary
Disease guidelines
WHO guidelines on CVD
prevention (14)
No
Website Online and downloadable
risk calculator available
at: www.nhlbl.nih.gov/
guidelines/cholesterol/
index/htm
Online and downloadable
risk calculators
available at:
www.heartscore.org
Online risk calculator
available at:
www.assign-score.com
Online risk calculator available at:
www.qrisk.co.uk
Online calculator available at:
www.chd-taskforce.
com/calculator
Charts downloadable at:
www.who.int/
cardiovascular_diseases/
guidelines/Pocket_GL_
information/en/index.html
Online calculator:
www.reynoldsriskscore.com
Internal
validation—
discrimination
AUROC men: 0.76
(0.75 to 0.78)
AUROC women: 0.79
(0.77 to 0.81)
AUROC high risk: 0.80
(0.80 to 0.82)
AUROC low risk: 0.75
(0.73 to 0.77)
AUROC men: 0.73
AUROC women: 0.77
QRISK2: AUROC men: 0.79
(0.79 to 0.79)
AUROC women: 0.82
(0.81 to 0.82)
AUROC 0.82 for coronary
events
AUROC 0.78 for cerebral
ischemic events
Not specified AUROC women: 0.808
AUROC men: 0.708
Internal
validation—
calibration
HL men: 13.48
HL women: 7.79
Not specified Observed 10-year CVD
incidence rates men:
11.7%; women 6.4%
Median ASSIGN men:
11.7%; women: 6.2%
Good correlation between
observed and predicted risks in
both men and
women—presented graphically
only— each decile of risk
Not specified Not specified HL women: 0.62
HL men: 12.9
External
validation—
discrimination
PRIME study Belfast: 0.68
(26)
PRIME study France: 0.66
(26)
Dutch study: 0.86 (0.84 to
0.88) (27)
Cleveland study: 0.57 (28)
China: men 0.75 (0.72 to
0.78) (29);
China: women 0.79 (0.74
to 0.85) (29)
THIN (UK): men 0.74 (0.73
to 0.74) (30);
women 0.76 (0.76 to
0.76) (30)
EPIC Norfolk: 0.71 (31)
UK women (BHHS): 0.66
(0.62 to 0.69) (32)
Dutch study: 0.85
(0.83 to 0.87) (27)
Cleveland study: 0.73 (28)
Norwegian study: range for
different age groups:
men 0.65 to 0.68 (33);
women 0.66 to 0.72
(33)
Austrian study: men 0.76
(0.74 to 0.79) (34);
women 0.78 (0.74 to
0.82) (34)
Icelandic study: 0.80 (0.78
to 0.82)—SCORE high
(35); 0.80 (0.77 to
0.82)—SCORE low (35)
Not assessed THIN database (UK): QRISK1:
AUROC men: 0.76 (0.76 to 0.77)
(30)
AUROC women: 0.79 (0.79 to
0.79) (30)
PRIME study Belfast: 0.61
(26)
PRIME study France: 0.64
(26)
Not assessed Not assessed
AUROC area under receiver operating characteristic curve; BMI bodymass index; CHD coronary heart disease; CRP C-reactive protein; CVD cardiovascular disease; Hb hemoglobin; HDL high-density lipoprotein; HL Hosmer Lemeshow; hsCRP high-sensitivity
C-reactive protein; LDL  low-density lipoprotein; MI  myocardial infarction; SBP  systolic blood pressure; WHO/ISH  World Health Organization/International Society of Hypertension. 1213
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Cardiovascular Risk Estimation Systems September 29, 2009:1209–27he Weibull model was also utilized in the most recent
ersion of the PROCAM system to allow a function to be
erived in women—for whom limited data were available
12). However, as demonstrated by the both the PROCAM
nd SCORE groups, the choice of Cox or Weibull makes
ittle practical difference to risk estimation.
Other more complicated methods also exist, including
luster analysis, tree-structured analysis, and neural net-
orks (39). These methods are particularly useful for
electing the most appropriate variables when a large num-
er of potential predictors of risk are available. Neural
etworks do not assume that risk factors function in a
onstant and continuous fashion and can account for com-
lex nonlinear relationships and interactions between risk
actors (22). Cluster analysis focuses on the identification of
roups of persons with similar risk factor characteristics who
ave similar levels of risk. However, there is difficulty in
btaining large epidemiological datasets with extensive
umbers of predictor variables available. Additionally, the
ecessity for measurement of multiple factors in clinical
ractice adds to complexity and is, therefore, likely to limit
linical usage of these systems. Tree-structured systems
ttempt to progressively split the population into smaller
ubgroups, through sequential introduction of the risk
actors, starting with the simplest. The advantage is that
ome persons can be classified as high or low risk based on
ery few risk factors, reducing unnecessary laboratory testing
or them. The main problem with all of these methods is
odel shrinkage—their predictive ability declines sharply
nce the model is applied to an external dataset, which
imits their utility in clinical practice (39).
The WHO/ISH (World Health Organization/International
ociety of Hypertension) risk prediction charts offer an advan-
age in that they have been developed for each specific WHO
ubregion (14). The disadvantage is the methodology. Only a
imited description of the methods has been provided (14).
his specifies that the charts were developed by creating a
ypothetical dataset for each region—on the basis of the risk
actor prevalence in that area, using the mean and standard
eviation of risk factor levels measured as part of the collabo-
ative risk assessment study (40). Each person was then
ssigned a relative risk, based on the combination of his or her
isk factor level and the relative risk associated with each risk
actor, as estimated from mainly prospective studies. The
elative risk for each person was then scaled according to the
aseline risk in that region, as estimated from the global
urden of disease study, in order to estimate the absolute risk.
hese methods require substantial further investigation to
etermine accuracy and validity, as acknowledged by the
uthors (14).
erformance: Internal and External Validation
he main ways to describe the performance of a risk
stimation system are discrimination, calibration, and re-
lassification. These are explained in Table 2. snternal validation. The assessment of model performance
n the dataset from which it was derived, internal validation,
s important in checking the mathematical performance of
he model used and appropriate fit of the model. As shown
n Table 3, risk estimations systems generally perform well
hen assessed in this way (8–12,20,21). However, the
erivation dataset (or a proportion of the same dataset from
hich the derivation dataset was drawn) is distinctly limited
n terms of comparing one function with another. These
ethods will be inherently biased toward the new function.
hat occurs not only because the exact baseline survival of
he population is included in the new function, but also
ecause the new function has been derived for prediction of
he exact end point in the test dataset, and identical risk
actor definitions are used in the test and derivation datasets.
herefore, assertions of superiority of new functions when
ssessed using the derivation dataset of the new function
hould be viewed with caution (10,11). Comparing the
erformance of functions in an external dataset is more
ppropriate.
xternal validation. External validation of the Framing-
am function has been assessed in numerous studies
26–32). Most external validation exercises were based on
ither the 1991 function of Anderson et al. (15) or the 1998
unction of Wilson et al. (16) that assessed risk of CHD
vents, as opposed to the 2008 function by D’Agostino et al.
8) that estimates risk of CVD incidence. In general,
xternal validations of Framingham functions have demon-
trated good discrimination, with area under the receiver-
perating characteristic curve (AUROCs) or C-statistics
anging from 0.66 to 0.88, as shown in Table 3, with some
xceptions (28,41). These have generally been higher in
omen. The discrimination in the elderly has been poorer,
s will be as discussed in following text (41).
Some external validation studies have shown poor dis-
rimination with the Framingham function. That may be
ue to a narrow age range (41), which does not allow for the
redictive ability of age as a risk factor or differences in end
oint definition. For example, the study by Aktas et al. (28)
howed SCORE to be a stronger predictor of CVD mor-
ality than the Framingham function; however, the Fra-
ingham function used was intended to estimate risk of
HD events, not mortality (28). Likewise, the low
UROCs of the Framingham function in the PRIME
tudy (26) may have been related to differences in ascertain-
ent of end points in the 2 studies because earlier versions
f the Framingham function included angina and silent
yocardial infarctions (42). The SCORE system has been
xternally validated in a number of studies, yielding results
imilar to Framingham, as shown in Table 3. The QRISK
ystem performed well when externally validated in the UK
HIN (The Health Improvement Network) GP register
30). Experience of the external validity of PROCAM is
ore limited (12). The ASSIGN-SCORE, QRISK2, and
he WHO/ISH investigators have not yet reported any
tudies of external validation.
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September 29, 2009:1209–27 Cardiovascular Risk Estimation SystemsJackson (43) has drawn attention to the fact that, because
n clinical practice a threshold is used for defining high/low
isk and treatment decisions are based around this, it is
mportant, in addition to reporting these measures of
ummary discrimination (AUROC and C-statistic), to con-
ider the discrimination at the threshold of high/low risk.
or example, for the SCORE function, the authors report
he sensitivity and specificity of the function at a variety of
ut-points for the threshold for high or low risk (9).
alibration. Calibration measures the agreement between
he observed and predicted. As demonstrated by Diamond
44), it is not possible to have a system with both perfect
alibration and discrimination. There is an inherent trade-
ff between the 2. They demonstrated a discrimination of
3% (AUROC) in a modelling exercise, when the function
as perfectly calibrated (44).
Risk estimation systems also change how well calibrated
hey are with time and place. Differences in the baseline
ates of CVD in different geographic regions mean that risk
stimation systems that are well calibrated in one region will
ead to overestimation or underestimation of risk in another
45). Likewise, secular changes in the incidence of CVD
ver time mean that risk estimation systems become out-
ated. For example, in most of the developed world, CVD
ncidence is now decreasing (13,46). That means that over
ime, risk estimation systems will start to overestimate risk.
onversely, in areas where CVD rates are still increasing,
urrent risk estimation systems will underestimate risk. The
HD mortality trends for men across time and place are
llustrated in Figure 1.
A systematic review by Brindle et al. (45) (Fig. 2)
emonstrated the calibration of the Framingham function
n several different cohorts. The function overestimated risk
n cohorts for which the baseline risk was lower than that of
Figure 1 CHD Mortality Rates in Men <65 Years Old
Global age-standardized coronary heart disease (CHD) mortality rates in men under
age 65 years (1950 to 2006). Figure drawn using World Health Organization statistics
(13). Dark blue line indicates Finland; red line, France; green line, Hungary; purple
line, Japan; dark red line, Ukraine; orange line, United Kingdom; light blue line, U.S.phe Framingham cohort, for example, cohorts in France and
ermany. The risk was underestimated in cohorts with a
orse baseline survival, for example, cohorts of diabetic
atients or patients with a family history of CHD. Good
alibration was demonstrated in cohorts that had similar
aseline CHD rates to Framingham at that time.
Risk functions can, however, be recalibrated to overcome
his problem. This recalibration process will be discussed in
he section on advances in risk estimation.
The net reclassification index is a novel method for
ssessing reclassification into more appropriate risk catego-
ies using new risk functions and is discussed in the
ollowing text.
sability, Inclusion of
ppropriate Risk Factors, and Effect
f Risk Estimation on Clinical Outcomes
isk estimation systems are of little value unless clinicians
ctually use them in day-to-day practice. Previous studies
ave shown that the format of the system affects the usage
f risk estimation systems and the accuracy with which
linicians use them (47). For example, simplifier color charts
ere shown to be preferred to more complicated numerical
ables (47). The SCORE chart (9), shown in Figure 3, is a
ood example of a simple, easy to use risk chart. The
CORE investigators acknowledge that the format of the
CORE charts is based on that of the original New Zealand
isk charts used in their guidelines (18). Some other formats
f current risk estimation systems are shown in Figure 4.
In general, electronic systems should be user friendly,
specially because previous studies have shown that health
are providers are less likely to use computerized systems,
ompared with simpler paper charts, even after training
49). An innovative solution to improving usability is the
ntegration of the risk estimation system with the GP
atabase. In this way, the risk estimate is automatically
alculated. The PREDICT-CVD system, an integrated
ystem developed to aid implementation of the New Zea-
and, resulted in a 4-fold increase in the rate of documen-
ation of risk estimates in the medical notes (50).
The risk chart format has several advantages in that it is
asy to use and inexpensive to produce. The SCORE chart
ombines ease of use and accuracy because the integer value
or the risk is displayed as well as the color-coded risk
ategory. Previous studies have shown inaccuracy of risk
stimates when color-coded charts alone are used (25). The
eakness of the paper chart is that only a limited number of
ariables can be incorporated.
Most of the current risk estimation systems include the
onventional risk factors: age, sex, smoking, blood pressure,
nd lipid levels. Recently, there has also been increasing
nterest in the inclusion of family history of CHD (10,
9–21), social deprivation measures (10,19), ethnicity (11),
nd interaction variables that adjust for the use of antihy-
ertensive medication (10,16,19). Inclusions such as social
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Cardiovascular Risk Estimation Systems September 29, 2009:1209–27eprivation may be considered particularly important in
ertain regions, for example, where social gradients in health
utcomes exist (10,19). Both Reynolds risk scores include
-reactive protein (CRP) (20,21). However, increasing the
umber of variables has advantages and disadvantages. For
xample, introducing a postal code-related measure of social
eprivation will limit the use of the function in regions outside
f this geographical region. One assumes that the more
ndependent CVD risk factors are included, the better the risk
stimate. However, the law of diminishing returns applies;
nce the basic risk factors are included, most of the predictive
bility has been realized and the addition of extra factors results
n only minor improvements (51), as will be discussed.
As more factors are included, the system becomes more
omplex, time consuming, and costly because a greater number
f risk factors have to be measured to estimate the risk. This
Figure 2 Observed to Predicted Risk
Observed to predicted risk demonstrated in external validation studies of Framingh
heart disease; CI  confidence interval; CVD  cardiovascular disease; RR  relancrease in complexity can impact the usage of the system. some have suggested the use of additional factors to refine the
isk estimate only in those at intermediate risk (52); this
pproach will be discussed in the following text.
Recently, there has been increasing interest in reducing
he number of measurements (particularly laboratory mea-
urements) required for risk estimation to increase ease of
se and cost effectiveness. For example, the use of body mass
ndex in place of lipid measurements has been shown to
esult in only minor reductions in discrimination of the
unction (8,53). The WHO/ISH risk charts are available in
ormats excluding lipid measurement (14); these are partic-
larly suited to areas in the developing world where access to
edical facilities is limited.
Although the performance and utilization of risk estimation
ystems are important, the bottom line is whether clinical
utcomes improve with their introduction. The limited re-
eprinted from Brindle et al. (45). CHD  coronary
k; WOSCOPS  West of Scotland Coronary Prevention Study.am. R
tive risearch into this area is addressed later in this review.
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September 29, 2009:1209–27 Cardiovascular Risk Estimation Systemsniversal Limitations of Risk Estimation
ystems and Recent Advances in Overcoming These
ne limitation of all risk estimation systems is that they
ssume constant effects of the risk factors at differing ages
nd levels of the other risk factors. The QRISK2 system
as attempted to overcome the problem of differing
ffects of the risk factors with increasing age by including
nteraction variables between age and several of the other
isk factors (11). However, this method still assumes that
he interaction effect with age remains constant at all
ges. Certain combinations of risk factors may act syn-
rgistically to increase risk in a manner that is more than
dditive. Cluster analysis and neural networks attempt to
ccount for this, but introduce other problems, as dis-
Figure 3 SCORE Chart for Use in High-Risk European Regions
CVD  cardiovascular disease; SCORE  Systematic COronary Risk Evaluation.ussed in the preceding text. The ideal situation would be oo have an extremely large dataset (a whole country or
ven continent) in which there were numerous persons
ith each combination of risk factors and to examine the
ctual (not calculated) risk within each combination. In
his way, particularly dangerous combinations of risk
actors could be identified. However, development of
uch a dataset would be practically impossible, especially
n the modern era when many of the identified risk
actors already have been treated.
ecalibration of Risk Estimation Systems
s mentioned previously, risk functions developed in one
egion will tend to overestimate or underestimate risk in
ther populations with different baseline risks (45,54),
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Cardiovascular Risk Estimation Systems September 29, 2009:1209–27ecause of either secular changes over time or regional
ifferences. The ideal solution to this problem would be the
ontinual generation of updated risk functions based on
ecent prospective cohort studies. While this is possible in
Figure 4 Formats for Some Current Risk Estimation Systems
(A) Interface for ASSIGN SCORE online calculator. (B) New Zealand risk chart (Fra
Group (18). (C) Portable Framingham risk calculator. (D) Joint British guidelines
diac Society et al. (48). Continued on next page.ome countries, for example, Finland (55) and Italy (56), ehis is not feasible in most areas. Recalibration of risk
stimation systems represents a viable alternative.
Two recent, region-specific pieces of information are
equired: the current national CVDmortality rates (or CVD
am adaptation), reprinted with permission from the New Zealand Guidelines
art (Framingham adaptation), reprinted with permission from the British Car-mingh
risk chvent rates) and representative surveys of risk factor levels in
1219JACC Vol. 54, No. 14, 2009 Cooney et al.
September 29, 2009:1209–27 Cardiovascular Risk Estimation SystemsFigure 4 Continued
(E) Sample WHO/ISH risk chart. (F) Interface for QRISK2 online calculator. (G) PROCAM scoring sheet. CHD  coronary heart disease; CVD  cardiovascular disease;
HDL  high-density lipoprotein; LDL  low-density lipoprotein; SBP  systolic blood pressure; TC  total cholesterol; TIA  transient ischemic attack.
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Cardiovascular Risk Estimation Systems September 29, 2009:1209–27he population. The current survival is taken to equate to the
aseline survival at the population mean level of risk factors.
his new baseline is then adjusted to the individual person’s
evel of risk factors, using the beta coefficients for each risk
actor from the original risk function (57). This approach
epresents a feasible option in many countries where current
ortality statistics are easily accessible and cross-sectional
Figure 5 Improved Calibration of Framingham Function in Chine
Calibration, predicted event rates (open bars) compared with actual coronary hear
the original Framingham function and (B) the recalibrated Framingham function in
ecalibrations of theramingham and SCORE Risk FunctionsTable 4 Recalibrations of theFramingham and SCORE Risk Functions
Recalibrated Versions
Framingham China (58)
U.S.—multiple ethnicities recalibration (57)
Britain—including 8 different ethnicities (59)
Asia (29)
Mediterranean countries (60)
SCORE Sweden
Germany (61)
Spain (62)
Greece/Cyprus (63)
Poland
the Netherlands (27)
Switzerland (64)urveys of risk factor distributions have been conducted.
he assumption here is that while the baseline survival
hanges from place to place and over time, the relative risks
r beta coefficients associated with each risk factor remain
he same.
Both the Framingham and the SCORE systems have
een recalibrated for several different regions, as detailed
n Table 4. The improvement in calibration is demon-
trated for the Chinese recalibration of the Framingham
unction in Figure 5 (58). However, the discrimination of
he function should remain virtually the same in the
riginal and recalibrated versions of the risk func-
ion (58).
One advantage of the SCORE system is that the use
f CVD mortality as the end point, as opposed to CVD
vents, facilitates the recalibration process (9), because
eliable and recent CVD mortality statistics are readily
vailable in many regions. This information is much
ess easily obtained and standardized when CVD event
ates are required, and regional differences in coding
epresent a difficulty in systems that include less hard end
oints (15,16). This advantage strongly influenced the
hoice of CVD mortality as the end point in the SCORE
roject (9).
ohort After Recalibration
se (CHD) event rates (solid bars), based on (A)
CS (Chinese Multi-Provincial Cohort Study). Reprinted from Liu et al. (58).se C
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September 29, 2009:1209–27 Cardiovascular Risk Estimation Systemsssessing the Value of Incorporating
ew Risk Factors Into Risk Estimation Systems
ecently, much attention has focused on trying to improve
isk estimation through the incorporation of new risk
actors. Traditionally, the improvement in discrimination of
isk estimation systems has been assessed by AUROC or
arrell’s C statistic. There have been several demonstra-
ions of the lack of improvement in discrimination, as
easured by AUROC with the addition of these risk
actors, despite the fact that many of these risk factors had
trong and independent effects on the further occurrence of
VD (11,51,52,65,66). Table 5 shows some examples of
he effect that inclusion of extra risk factors had on discrim-
nation, as measured by AUROC.
However, AUROC was a technique developed for assess-
ng the performance of a diagnostic test that has a straight-
orward yes/no answer, against that of a gold standard. A
erfectly sensitive and specific test will result in an AUROC
djusted Odds Ratios for Risk Factors Newly Incorporated in Riskmprov ment in AUROC Afforded by Their Incorporation With Net RTable 5 Adjus ed Odds Ratios f Risk Factors Newly IncorporaImprovement in AUROC Afforded by Their Incorporation
Risk Factor Study Odds Ratio
Multiple biomarker
score: BNP, CRP,
homocysteine,
renin, urinary
albumin-to-
creatinine ratio (66)
Framingham Offspring
Study
1.84 (1.11–3.05)
comparing the high
quintile to the lowest
2 quintiles of
multimarker score
Cardio
MI,
stro
HDL cholesterol (51) Framingham 0.65 (0.53–0.80) for
each 1 SD increase
in HDL
Coron
MI,
ins
HDL cholesterol (67) SCORE dataset Women 0.60
(0.51–0.69); men
0.76 (0.70–0.83) per
0.5 mmol/l increase
in HDL
Cardio
Heart rate (68) The national FINRISK
study
Men 1.19, women 1.20
per 10 beats/min
increase in resting
heart rate
Cardio
hsCRP—women only
(65)
Women’s Health Study hsCRP: 1.22 per 1-U
increase in log
(hsCRP)
CVD i
stro
rev
dea
hsCRP (52) Framingham Offspring
Study
1.34 (1.14–1.58) for
each 1-U increase in
log (hsCRP)
MI an
Ethnicity and chronic
diseases and
interactions
between age and
several other risk
factors (11)
QRISK2 Ethnicity: 8 ethnicities
ranging from 1.97
(Pakistani women) to
0.51 (Chinese
women) compared
with white women
Atrial fibrillation: 3.06
in men
Renal disease: 1.70 in
men
Cardio
CHD
HbA1c EPIC Norfolk CHD i
NP  B-type natriuretic peptide; NS  not significant; TIA  transient ischemic attack; other abf 1. However, because risk estimation is just that, an tstimate, a perfect AUROC will never be achieved. The
ighest AUROCs for risk estimation achieved to date have
een in the region of 0.88, when tested on the same data
rom which they were derived (21). The usual AUROCs of
isk estimation systems are in the region of 0.75 to 0.80.
hen one considers that age and sex alone can result in an
UROC of up to 0.70, clearly there is little room for
mprovement in AUROC with addition of risk factors
eyond the conventional risk factors.
For this reason, there has been increasing interest in the
evelopment of more appropriate methods for assessing the
mprovement in performance afforded by incorporation of
ew risk factors (69). The method with most potential for
linical utility is reclassification.
Clinically, the most important feature of a risk estimation
ystem lies in its ability to classify persons to appropriate risk
ategories, because treatment decisions are based on these
lassifications (43). Appropriate risk categories are those
ion andsific tion (Where Available)n Risk Function and
h Net Reclassification (Where Available)
End Point Improvement in AUROC Net Reclassification Index
lar disease incidence:
ry insufficiency,
d heart failure
0.76–0.77
art disease incidence:
pectoris, coronary
cy, or CHD death
0.762–0.774 12.1%, p  0.001
lar mortality 0.808–0.814 2.2%, p  0.006
lar mortality 0.879–0.881 1.1%, p  NS
ce: MI, ischemic
ronary
rization, and CVD
0.813–0.815 5.7%, p  0.0001
death 0.863–0.865 11.8%, p  0.009
lar disease incidence:
ke, TIA
Women 0.814–0.817,
men 0.788–0.792, for
all additions combined
ce Men 0.72–0.73,
women 0.80–0.80
3.4% (p  0.06 in men);
2.2% (p  0.27 in women)
ons as in Table 3.Functeclasted i
Wit
vascu
corona
ke, an
ary he
angina
ufficien
vascu
vascu
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ke, co
ascula
ths
d CHD
vascu
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nciden
breviatihat are close to a threshold at which an intervention
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Cardiovascular Risk Estimation Systems September 29, 2009:1209–27ecommendation is likely. Improvement of discrimination
f a function in those at intermediate risk is particularly
mportant (65).
A new method for assessing for superior classification has
een developed by Pencina et al. (51). This measure, the net
eclassification index (NRI), determines the net percentage
f those who do and do not have an event over the
bservation time who are correctly reclassified using the new
unction. For example, in a person who develops the end
oint, upward movement to a higher risk category, when
sing the new risk function, would be considered correct
eclassification (51).
This system has the advantage over previous reclassifica-
ion measures of quantifying the reclassification in the net
orrect direction, as opposed to reporting the overall reclas-
ification that occurs on addition of the new factor (51,65).
able 5 shows the NRIs associated with incorporation of
arious risk factors in risk estimation functions.
An interesting exploratory analysis by the Framingham
roup calculated the change in AUROC when risk factors
ere sequentially added to a model initially containing only
ge and sex (52). The risk factors were entered in the
ollowing order: systolic blood pressure, lipids, smoking,
iabetes mellitus, and CRP. The increases in AUROC
ecame sequentially smaller with each additional risk factor:
.740, 0.767, 0.787, 0.795, and 0.799 for the listed risk
actors, respectively. However, in spite of the relatively
inor increases in AUROC, most of the additions were
ssociated with improvements in reclassification, as mea-
ured by NRI: 10.8%, 7.0%, 7.7%, 0.5%, and 5.6% for
ach of the risk factors, respectively. The authors emphasize
he fact that the value of incorporating risk factors is
ependent on the order in which the risk factors were added
o the model (52).
The exact utility of this system has yet to be determined.
ome have suggested that those risk factors that provide
uperior classification could be measured in those at inter-
ediate risk. High-sensitivity CRP has been suggested as a
otential extra risk factor to measure in those at intermedi-
te risk to further define risk in this group (52,65). It has
een pointed out that the NRI depends strongly on the
hresholds chosen for the risk categories (51). Therefore, it
as been suggested that risk categories routinely used in
linical practice for decision making should be used in
ssessing reclassification (51).
isk Estimation in Younger Persons
ounger persons will always be at low absolute risk (an
bvious exception will be genetic defects that result in
xtreme levels of risk such as homozygous familial hyper-
holesterolemia), even when risk factor levels are very
nfavorable. For example, looking at the 40-year age band
f the SCORE chart in Figure 3 (9), no combination of risk
actors will place a person in the high-risk category (5%
0-year risk of fatal CVD). Even a 40-year-old man who iseverely hypertensive, severely hypercholesterolemic, and a
moker will still only have a risk of 4%. The same situation
ccurs with use of the Framingham function. For example,
study by Cavanaugh-Hussey et al. (70) points out that
nly the combination of current smoking and low high-
ensity lipoprotein cholesterol could place a woman under
he age of 65 years in the high-risk group based on the ATP
Adult Treatment Panel) guidelines (70). A similar situation
as noted for men 45 years of age.
This represents a challenge when counseling these
ounger persons regarding the need for modification of
ifestyle to reduce their risk (71). This is an important issue
ince modification of risk factors at this early stage affords
he greatest opportunity for prevention of CVD. The earlier
ersion of European guidelines recommended calculating
hat the person’s risk would be at age 60 years if current risk
actor levels were maintained (4). However, this was inter-
reted too literally by some, who suggested that this
pproach resulted in overmedication of the young (72). In
he Fourth Joint Task Force guidelines, an alternative
pproach is provided: the relative risk chart (Fig. 6) (2).
This chart provides an estimate of the risk of a person
ith a certain combination of risk factors compared with a
erson of the same age and sex who has ideal risk factor
evels. This relative risk may aid the physician in commu-
icating to younger persons that although they are at low
bsolute risk, their risk is still “x” times higher than it could
e if they had ideal risk factor levels. Taking the example of
he 40-year-old hypertensive, hypercholesterolemic smoker,
is low absolute risk of 4% equates to a relative risk of 12
imes that of a man of his own age with ideal risk factor
evels.
Other suggested methods for communicating regarding
isk with younger persons include the calculation of lifetime
isk, risk age, risk advancement periods, and expected
urvival. Lifetime risk is the risk of CVD developing in a
erson at some point during his or her lifetime (73). Using
his method, the risk is highest for younger persons because
hey have a longer time available in which to develop the
isease.
Figure 6 Relative Risk Chart
This chart may be useful in explaining to a younger person that, even if his or
her absolute risk is low, it may still be 10 to 12 times higher than that of a
person of a similar age with low risk factors.
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September 29, 2009:1209–27 Cardiovascular Risk Estimation SystemsCalculation of the individual person’s risk age is another
lternative that is easily understood (8,74). Using this
ystem, the risk is expressed as extra life-years. Rate ad-
ancement periods can also be useful in communicating risk.
his metric can be used when the risk of a disease (e.g.,
VD) increases progressively with age. The rate advance-
ent period is the average time period by which a certain
ate (or risk for risk advancement period) of CVD is
rematurely reached in subjects exposed to a risk factor or
ombination of risk factors (75). Another option that is
resently being explored is the calculation of the expected
urvival (or life expectancy) associated with a combination of
isk factors.
As pointed out by Hense (76), the risk chart format can
e particularly useful for communication about risk. As well
s showing absolute and relative risk, the chart can also be
sed by the physician to roughly calculate both risk age and
isk advancement period (76). For example, the 40-year-old
moking, hypertensive, hypercholesterolemic man could be
old that he has a “CVD risk age” of 65 years, since his
0-year CVD mortality risk is the same as that of a
5-year-old nonsmoking man with ideal risk factor levels,
ased on the SCORE chart (Fig. 3). The corresponding risk
dvancement period would be 25 years.
isk Estimation in the Elderly
urrent risk estimation systems vary in the age ranges to
hich they apply. Most can be used up to age 75 years
8,10–12). However, the SCORE function concentrates on
he middle-aged group and is only recommended for use in
he 40- to 65-year age range (9).
The use of risk estimation systems between the ages of 65
nd 75 years is problematic because most of these systems were
erived from cohorts of primarily middle-aged people, with
lder persons under-represented in the derivation cohorts. The
ame beta-coefficients for the risk factors were applied at all age
anges, meaning that the risks associated with risk factors in
ounger persons have been extrapolated to the older age
roups. Substantial evidence points to the fact that although
ost conventional risk factors still function in the older age
roup, the relative importance of the risk factors changes with
ge (77), and therefore this use of the same beta-coefficients in
ll age groups may be inappropriate.
For example, in the INTERHEART study, hyperten-
ion, smoking, dyslipidemia, and diabetes remained signif-
cant risk factors for myocardial infarction in the 60 years
ge group but with significantly lower hazard ratios than for
hose in the 60 years age group (77). Conversely, in men
60 years of age, moderate alcohol consumption and
hysical activity became more important protective fac-
ors (77). (See Online Figure 1 for illustrations of these
elationships.)
The accuracy of risk estimation has recently been shown
o be substantially lower in older persons than in middle-
ged persons (41,78,79). An analysis of the performance of the Framingham function in initially healthy 85-year-old
ubjects in the Leiden 85 Plus study showed very poor
iscrimination, with an AUROC of only 0.53, which was
ot significantly different from 0.50 (95% confidence inter-
al: 0.43 to 0.64) (41). A function derived from the Leiden
5 Plus study and containing the same conventional risk
actors resulted in a similarly low AUROC. In fact, of a
umber of risk factors and biomarkers, only homocysteine
as a significant predictor of CVD mortality in this group.
t should be remembered that age, which is the strongest
ontributor to the discrimination of virtually all risk func-
ions, could not function in this cohort because all of the
roup’s members were the same age at baseline. This
ontributes to the remarkably low AUROC. The dataset for
his study was small: 302 participants with 35 events. Another
tudy from the Netherlands of persons 70 years of age
howed similarly poor discrimination, with AUROCs of 0.55
nd 0.60 for the PROCAM and Framingham functions,
espectively, for the prediction of CVD mortality (79).
Two recent studies have shown a significant improvement
n discrimination of risk estimation systems in the elderly
ith the addition of a range of biomarkers including
nterleukin 6, CRP, troponin I, N-terminal pro–B-type
atriuretic peptide, cystatin C, and carotid plaque burden.
owever, these improvements were based on internal vali-
ation and require confirmation in external studies.
An extension of the SCORE system is currently being
eveloped. This system, SCORE O.P., will be derived
ntirely from a cohort 65 years of age at baseline. The
ystem will utilize only the risk factors that remain signifi-
ant predictors of CVD in the older age groups and will
liminate the problem of applying beta-coefficients derived
rom studies of younger persons to older persons. This
lteration in derivation methods for the function may result
n an improvement in risk estimation and may represent a
ore convenient approach to the measurement of multiple
iomarkers in older people.
The second version of the QRISK function includes
nteractions between age and several other risk factors
11). The inclusion of these interactions allows for some
f the difference in effect of risk factors at different ages.
his inclusion may result in superior risk estimation in
lder age groups; however, this issue has not been
xamined to date.
Attempts to improve risk estimation in the older age
roup, however, will only solve one part of the problem of
VD prevention in the elderly. The other aspect that needs
o be considered is what level to consider high risk (80). For
xample, using the SCORE function, all men 65 years of
ge will have a 10-year CVD risk 5%, and some have
uggested that this can result in overmedication of older
ersons (80). The latest version of the European guidelines
n CVD prevention recommends that a higher threshold of
0% may be considered high risk in older people (2).
Although recent randomized controlled trials of preven-ive measures in older and even very old persons have
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t is still uncertain whether risk stratification can assist in
argeting these measures toward those who will benefit
ost, and if so, what threshold is appropriate in this age
roup. This issue requires further research.
isk Estimation Systems and Outcomes
he vast majority of guidelines on CVD prevention now
ecommend that the intensity of preventive measures should
e based on a person’s total CVD risk (2,14,25). However,
ith the exception of the MRFIT (Multiple Risk Factor
ntervention Trial) (82), which was undertaken at a time
hen risk factor treatments were of limited efficacy and
gainst the background of falling CVD mortality rates,
here has been no trial comparing the success of this
pproach with an ad-hoc, unifactor-based approach. The
esults of such a trial are not easy to predict. The unifactor
pproach might result in overtreatment of many persons
ith isolated risk factors and low total risk, and undertreat-
ent of those who do not reach conventional risk factor
hresholds for treatment of any one risk factor, yet are at
xtremely high total risk because of the combined effect of
ultiple factors.
Conversely, because the unifactor approach could result
n treatment of a larger absolute number of people, it may
esult in a greater overall number of events avoided. How-
ver, the benefits of estimating total CVD risk and treating
ccordingly are 2-fold. The first is the direction of preven-
ive efforts toward those who will be most likely to benefit.
he second is the reassurance and avoidance of side effects
n lower-risk persons who will, as a group, derive less benefit
83), which also has obvious economic implications. We
uggest that if such an analysis were conducted, as well as
alculating the benefits in both groups, adverse events in
ach group and costs should also receive due consideration.
While no specific evidence demonstrating the value of the
igh-risk approach is available, the logic of the approach is
upported by the results of trials of pharmacotherapy for the
revention of CVD. Table 6, adapted from Jackson et al.
83), demonstrates the greater absolute risk reduction for
troke and CHD observed in randomized controlled trials of
bsolute and Relative Risk Reductions Demonstrated in Meta-Analf Blood Pressure- and Lipid-Lowering Treatmen in Higher- and LowTable 6 Absolute and Relative Risk Reductions Demons ratedof Blood Pressure- and Lipid-Lowering Treatment in Hig
Lipid-Lowering
Baseline Risk of Trial Participants A
Few or no participants had a history of vascular disease
Most or all of participants had a history of vascular disease
Blood Pressure-Lowe
Ab
Few or no participants had a history of stroke
Most or all of participants had a history of strokedapted from Jackson et al. (83).
CHD  coronary heart disease.lood pressure and lipid-lowering treatment of those at
igher baseline risk (due to pre-existing disease in this case)
han lower-risk persons, despite an equivalent or even
igher relative risk reduction. An interesting analysis by the
ame group calculated that the number needed to treat to
revent 1 CVD event in 5 years when using 3 preventive
nterventions (aspirin, lipid lowering, and blood pressure
owering) was only 6 in the very-high-risk group (30%
-year risk of CHD) compared with 36 in the low-risk
roup (5% 5-year risk of CHD) (18).
The other question regarding risk estimation systems and
heir effects on outcome is whether the provision of risk
stimation systems to health care professionals and/or the
ommunication of information regarding total CV risk to
atients results in benefit in terms of risk factor reduction.
f course, that will depend critically on the actual uptake of
he system. Some smaller randomized controlled trials have
ddressed this issue (methodological details and results are
escribed in Online Table 1) (49,74,84–87). Of note, there
s substantial heterogeneity in both the designs and results
f these studies. While most have shown a significantly
reater reduction in risk factors in the intervention group, in
eneral, the magnitude of the effect has been small. For
xample, CHAS (Cardiovascular Health Assessment Study)
nd the CHECK-UP (Cardiovascular Health Evaluation to
mprove Compliance and Knowledge Among Uninformed
atients) study both showed greater improvements in cho-
esterol profiles and coronary risk scores in the intervention
roup. Four of the trials demonstrated greater reductions in
lood pressure in subjects assigned to the risk estimation
ystem intervention (49,74,84,86).
Particularly in the case of the study by Hanon et al. (87),
he follow-up period may have been too short to detect a
ifference. For example, mortality benefits in the MRFIT
rial among those randomized to the special intervention
roup only appeared after 10 years of follow-up (82).
ecause the majority of studies included patients already at
ubstantial risk, in general, they failed to consider the
eductions in treatment of low-risk persons. This underes-
imates the value of risk estimation as mentioned in the
revious text.
sk Groupsta-Analyses
and Lower-Risk Groups
Meta-Analysis
e Risk Reduction (CHD) Relative Risk Reduction (CHD)
.0% (1.7%–2.3%) 24% (17%–30%)
.4% (3.1%–3.6%) 24% (18%–21%)
rials Meta-Analysis
Risk Reduction (Stroke) Relative Risk Reduction (Stroke)
.4% (1.2%–1.5%) 35% (29%–41%)
.4% (3.4%–5.4%) 24% (14%–34%)yseser-Riin Me
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September 29, 2009:1209–27 Cardiovascular Risk Estimation SystemsIt is interesting to note that the studies that yielded the
ost promising results in terms of reduction in risk
actors are the studies in which the patient was actually
iven the results of the risk profile (74,85). Additionally,
oth of these risk profiles included a presentation of the
V risk age, a measure that intuitively should be more
omprehensible to the individual patient. This finding
uggests that using risk estimation systems to emphasize
o patients how elevations in their risk factors combine
ith each other to affect their risk of future disease
mproves both adherence to lifestyle advice and compli-
nce with medication. Indeed, research has demonstrated
hat much of noncompliance with lipid-lowering medi-
ation is due to discontinuation by patients who fail to
nderstand that their medication is still required.
onclusions
n most people, atherosclerotic CVD is the product of more
han 1 risk factor. A combination of several seemingly
odest factors may result in a much higher total risk than a
ingle, more impressively raised factor. Therefore, systems
o help estimate total risk have been developed.
Most systems perform similarly in terms of discrimina-
ion (the ability to separate those who will develop an end
oint from those who will not). However, calibration (how
losely predicted outcomes agree with actual outcomes) may
ary widely if a risk estimation system is applied to a
ifferent population, or to a population that has seen a marked
hange in CVDmortality between the time when the function
as derived and when it is applied. That can be dealt with by
eriving a new system from a local and more contemporaneous
ohort study. Often this will not be feasible, in which case
ecalibration is a practical alternative.
The addition of new risk factors often has a disappoint-
ngly small effect on overall performance, but can be useful
n correctly reclassifying those at intermediate risk as above
r below a chosen intervention threshold.
Young persons at low absolute but high relative risk of
VD need thought. Possibilities to illustrate their increased
isk include relative risk charts and the calculation of
ifetime risk, risk age, or risk advancement periods. The
stimation of risk in the elderly remains a challenge.
While estimating total risk seems eminently logical, more
esearch is required to quantify the clinical benefits—if
ny—and cost effectiveness of such an approach. But a
reater problem is the underutilization of CVD prevention
uidelines in clinical practice, and the real challenge is not to
oncern ourselves with competition as to which method of
isk assessment is better but rather to encourage day-to-day
isk evaluation and management.
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